We are live on ! Find out more
PROK icon

ProKidney
PROK

90 hedge funds and large institutions have $223M invested in ProKidney in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

86% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 7

7% more funds holding

Funds holding: 84 → 90 (+6)

0% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 15

0.56% less ownership

Funds ownership: 89.97% → 89.42% (-0.56%)

1% less capital invested

Capital invested by funds: $225M → $223M (-$2.48M)

Holders
90
Holders Change
+6
Holders Change %
+7.14%
% of All Funds
1.38%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
15
Reduced
15
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RIA
RP Investment Advisors
Ontario, Canada
+$5.33M
2
LCM
LH Capital Markets
New York
+$4.94M
3
CAC
Cowen and Company
New York
+$3.18M
4
SC
Sculptor Capital
New York
+$1.64M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$1.17M

Top Sellers

Rank Fund Capital Flow
1
BCM
BlueCrest Capital Management
Jersey
-$5M
2
MS
Maven Securities
Jersey
-$4.9M
3
AC
Athanor Capital
New York
-$3.92M
4
SSA
Schonfeld Strategic Advisors
New York
-$3.92M
5
GCL
Glazer Capital LLC
New York
-$1.84M
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
26
Saba Capital Management
New York
$2.48M – – –
MCM
27
Moore Capital Management
New York
$2.48M – – –
WA
28
Whitebox Advisors
Minnesota
$2.48M – – –
LCG
29
Luxor Capital Group
New York
$2.33M – – –
MA
30
MYDA Advisors
New York
$2.3M -$7.15K -723 -0.3%
GCM
31
Ghisallo Capital Management
Massachusetts
$2.23M – – –
APM
32
Avidity Partners Management
Texas
$1.98M – – –
DKCM
33
Davidson Kempner Capital Management
New York
$1.97M – – –
AA
34
AQR Arbitrage
Connecticut
$1.89M -$88K -8,900 -4%
BI
35
Bulldog Investors
New Jersey
$1.87M -$63.6K -6,432 -3%
VI
36
Vestcor Inc
New Brunswick, Canada
$1.73M – – –
PAMP
37
Polar Asset Management Partners
Ontario, Canada
$1.68M – – –
WCM
38
Whitefort Capital Management
New York
$1.59M +$1.59M +160,615 New
Jane Street
39
Jane Street
New York
$1.49M +$2K +202 +0.1%
HP
40
Hound Partners
New York
$1.49M – – –
FLC
41
Fifth Lane Capital
Texas
$1.49M +$1.48M +150,000 New
PSAMP
42
P. Schoenfeld Asset Management (PSAM)
New York
$1.43M +$440K +44,534 +45%
EAM
43
Exos Asset Management
New York
$1.26M +$273K +27,594 +28%
RCM
44
Radcliffe Capital Management
Pennsylvania
$1.24M – – –
SCM
45
Silverarc Capital Management
Massachusetts
$1.23M +$177K +17,862 +17%
Citadel Advisors
46
Citadel Advisors
Florida
$1.19M +$30.2K +3,055 +3%
BCM
47
BlueCrest Capital Management
Jersey
$1.18M -$5M -505,619 -81%
CPM
48
Crescent Park Management
California
$1.08M +$5.69K +576 +0.5%
WC
49
Wealthspring Capital
New York
$1.07M +$15.8K +1,603 +1%
KPF
50
K2 Principal Fund
Ontario, Canada
$990K -$391K -39,524 -28%
1
2
3 4

PROK Hedge Fund Activity: Q4 2021 in Review

90 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in ProKidney (PROK) for Q4 2021, worth a combined $223M — down 1.1% from $225M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new PROK positions and 7 closed out — a net gain of 6 holders — while 15 added to existing stakes and 15 trimmed.

The largest buyer was RP Investment Advisors, opening a new position worth an estimated $5.33M. The largest seller was BlueCrest Capital Management, cutting an estimated $5M.

  • 90 institutional investors held ProKidney (PROK) as of Q4 2021, up from 84 in Q3 2021.
  • Funds reported $223M of ProKidney stock for Q4 2021, down 1.1% quarter-over-quarter.
  • 13 funds opened new ProKidney positions in Q4 2021 and 7 closed out, a net change of +6 holders.
  • The largest ProKidney buyer in Q4 2021 was RP Investment Advisors, an estimated $5.33M added.
  • The largest ProKidney seller in Q4 2021 was BlueCrest Capital Management, an estimated $5M sold.

Based on aggregated 13F filings for Q4 2021.